Double attack on prostate cancer: testing a drug combo for tough cases
NCT ID NCT03344211
Summary
This study is for men with advanced prostate cancer that has stopped responding to standard hormone therapy and has spread to the bones. It aims to see if adding a targeted radiation drug (Radium223) to a standard cancer-fighting pill (enzalutamide) works better than the pill alone. Researchers will check how the treatments affect the cancer in the bone and the body's immune response.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CASTRATION-RESISTANT PROSTATE CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cedars Sinai Medical Center
Los Angeles, California, 90048, United States
-
City of Hope
Duarte, California, 91010, United States
-
USC / Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
Conditions
Explore the condition pages connected to this study.